Apnimed, Inc.

APMD

Healthcare Biotechnology

Apnimed, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $38.5 million, up 380.1% from fiscal 2024.

15.10 0.94 +6.64%
Market cap
$628.6M
P/E
0.8×
Fwd P/E
4.3×
Dividend yield
—
F-score
n/a
ROIC
0.00%
Net debt / EBITDA
0.0×
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Jun '25 Older periods
ROE
0.00% — — —

+2 more TTM periods

ROA
0.00% — — —
ROIC
0.00% 0.00% 0.00% —
Return on Tangible Assets
64.01% 0.00% 0.00% —
Average Days of Receivables
2.15 0.00 0.00 —
Free Cash Flow per Share
(17.46) 0.00 — 0.00
Free Cash Flow
(83.75) — — —
Other line items

Show all line items

Columns are period end dates · fundamentals updated 2 Nov 2026